Next-Level Care: Generative AI Poised for $22B Growth in Healthcare
Riepilogo
The generative artificial intelligence (AI) market for healthcare is valued at more than $1 billion as of 2022, and it is projected to swell to nearly $22 billion by 2032. Technology giants, venture capitalists and private equity firms will play a significant role in that market, acting as investors, partners and innovators. Meanwhile, healthcare companies — including providers, payers, pharmaceutical companies and others — recognize generative AI’s potential to transform health and medicine and are teaming up with tech giants and startups to introduce cutting-edge AI technology to all aspects of care — from research to treatment to billing. The “Generative AI Tracker®” delves into the current state and future potential of generative AI in healthcare. It explores various use cases, examines issues and challenges, and offers examples of emerging regulations. This edition highlights select startups addressing complex healthcare challenges, including drug discovery, patient care and clinical decisions. Generative AI Companies Stand Poised to Transform the Care Continuum Healthcare-focused companies and startups are turning to generative AI innovations to tackle complex drug discovery, diagnostic testing and patient care challenges. They are securing investments, emerging from stealth mode and announcing new clients. In some instances, they are also being acquired, following a pattern commonly seen when technology becomes more established. To learn more, visit the Tracker’s Companies of Note section. Generative AI Can Improve Medical Research, Drug Development and Patient Care Large language models (LLMs), the core of generative AI, offer many applications beyond drug discovery, promising to reshape other aspects of healthcare, including provider-patient interactions and care delivery. The U.S. Department of Health and Human Services (HHS) maintains a growing list of complex and detailed AI use cases deployed or in development within the federal government. To learn more, visit the Tracker’s Innovation and Use Cases section. Generative AI’s Technology Is Not Fully Optimized for Healthcare Generative AI faces many growing pains as it seeks its footing. In a recent survey, management consulting firm Bain & Company revealed that the main barriers to generative AI in healthcare are a lack of resources, expertise and regulation, with data access and quality and organizational resistance close behind. The recurring theme across industry studies is that generative AI in healthcare is nascent and needs time to prove its efficacy and to earn public trust. To learn more, visit the Tracker’s Issues and Challenges section. About the Tracker The “Generative AI Tracker®,” a collaboration with AI-ID, delves into the current state and future potential of generative AI in healthcare. This edition examines the role that generative AI can play in transforming critical aspects of healthcare, from research to treatment.The post Next-Level Care: Generative AI Poised for $22B Growth in Healthcare first appeared on PYMNTS.com.
In "This Is How They Tell Me the World Ends," Nicole Perlroth, a former New York Times reporter, offers a detailed picture of how the zero-day exploit tra…
In "This Is How They Tell Me the World Ends," Nicole Perlroth, a former New York Times reporter, offers a detailed picture of how the zero-day exploit trade developed and affects critical infrastructure.
The post First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP? appeared first on Coinpedia Fintech News On January 11, the U.S. Securities and Exchang…
First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP?
Denaro elettronico · Blockchain · Servizi per le banche
Riepilogo
The post First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP? appeared first on Coinpedia Fintech News On January 11, the U.S. Securities and Exchange Commission (SEC) approved the first Spot Bitcoin ETF. Four months later, the SEC approved another spot ETF, this time for Ethereum. This highlights the SEC’s evolving stance toward crypto adoption. Meanwhile, Crypto analysts at Standard Chartered weighed in on the potential ETF launch for other altcoins. Solana & XRP ETFs On The Line With Ethereum ETFs now on the market, attention is shifting towards other potential candidates for ETF approval. Geoffrey Kendrick, Head of Forex and Digital Assets Research at Standard Chartered Bank, suggests that Solana (SOL) and XRP ETFs could be approved as early as 2025. JUST IN: Standard Chartered analyst Geoffrey Kendrick said that cryptocurrency ETFs such as SOL and XRP may be approved in 2025, and the approval of the ETH ETF means that ETH and similar cryptocurrencies will not be classified as securities. pic.twitter.com/RECYwTnVRr— SolanaFloor (@SolanaFloor) May 24, 2024 Kendrick further highlights that the SEC’s treatment of Ethereum could set a precedent for other cryptocurrencies. He points out that if Ethereum is not considered a security, other coins with similar characteristics, such as Solana and XRP, might also evade this classification. Kendrick notes that the recent approval of Ethereum ETFs implies that ETH-like coins, which share similar technological foundations, may not be classified as securities by the SEC. The Future of Crypto ETFs Crypto analyst The Birb Nest observes that the narrative around a Solana ETF is gaining momentum on crypto Twitter and among media outlets. He suggests that while regulation will take time, the anticipation of a Solana ETF is growing. In the meantime, market participants are encouraged to drive a “full-blown meme mania” around Solana, similar to the hype seen with meme tokens like Dogecoin (DOGE) and Shiba Inu (SHIB). They will try to push the narrative that $SOL is another ETF.This will probably happen, but they definitely need more time and they need to introduce a legitimate #crypto regulatory framework.It will take time, but before they do that in the meantime we can unleash a… https://t.co/kHDZ1SMTwx— THE ₿IRB NEST (@TheBirbNest) May 24, 2024 BTC+ETH dominance will rise’ However, Kendrick predicts that Bitcoin and Ethereum will continue to dominate the market. He expects a strong inflow of investments into spot Bitcoin ETFs, projecting a potential BTC price target of $150,000 by the end of the year. This expected increase in Bitcoin and Ethereum dominance suggests that they will remain key players in the evolving landscape of cryptocurrency ETFs. As the SEC continues to pave the way for more crypto ETFs, the future looks promising for digital assets like Solana and XRP.
The post Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5? appeared first on Coinpedia Fintech News Bullish clouds are h…
Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5?
Denaro elettronico
Riepilogo
The post Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5? appeared first on Coinpedia Fintech News Bullish clouds are hovering over the crypto space as traders have become optimistic, followed by the approval of the spot Ethereum ETF. The traders became more sure of the next price action when the ETH price surged magnificently but fell short of a few dollars in reaching $4000. In the meantime, some altcoins have been maintaining a steep upswing while some are recording new ATH like Ondo, which has surged over 15% in the past 24 hours. After such a massive rally, many may expect a bearish pullback, but from a larger perspective, the token appears to be preparing for a fresh upswing, targeting another 40% upswing. The SEC approving the spot ETH ETF has catalysed the ongoing bullish upswing which has also led to the speculations of an altseason in a short while. ONDO price shot up by over 20% to reach $1.16 after consolidating below $1 for a few days. With this, the accumulated bullish momentum may assist a continued upswing for the rest of the month. As seen in the above chart, the ONDO price has been maintaining a strong bullish trend since the beginning. Meanwhile, the price is facing some hindrances in rising above the average bands of the rising parallel channel, but the bulls may lift the levels very soon. The RSI is in an incremental stage and may surge to reach within the overbought levels. This may offer the required push, but the price may refrain from reaching the upper resistance level of $1.5. Besides, the volume is also slowly piling up, which is offering the bulls the required momentum. Hence, the Ondo price is expected to maintain an elevated trend until the end of the month and discover new highs. Nevertheless, the price could rise and hit the upper resistance levels at $1.5 in the first few days of June, which will be a decisive phase for the token. If bulls hold their dominance, then a breakout could occur; otherwise, a rejection may cause the price to test lower support levels until it finds a strong base to trigger a rebound.